Appointment dossier — Lung Adenocarcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Lung Adenocarcinoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT04339218 · Phase 3 — Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma (France)
- NCT06500455 · Phase 3 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain (United States)
- NCT05431270 · Phase 1 / Phase 2 — Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) (United States)
- NCT05267626 · Phase 1 / Phase 2 — Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (United States)
- NCT05024214 · Phase 1 / Phase 2 — Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (China)
- NCT07174583 · Phase 1 / Phase 2 — A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer (United States)
- NCT06472388 · Phase 2 — Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors (Brazil)
- NCT07483983 · Phase 2 — Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (France)
- NCT04787042 · Phase 1 / Phase 2 — Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (United States)
- NCT06394674 · Phase 2 — High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib (China)
- NCT04459065 · Phase 1 / Phase 2 — Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery (Canada)
- NCT06749691 · Phase 2 — Liposomal Irinotecan and Apatinib in ES-SCLC (China)
- NCT05502913 · Phase 2 — Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer (Israel)
- NCT06618287 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (United States)
- NCT07325136 · Phase 1 / Phase 2 — A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer (United States)
- NCT07309952 · Phase 2 — Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC (China)
- NCT07084610 · Phase 2 — Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer (Brazil)
- NCT05799274 · Phase 1 — Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors (United States)
Most-relevant first: trials that name Lung Adenocarcinoma, then broader trials you may still qualify for. 284 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Has my tumor been tested for EGFR activating mutations (ex19 del, L858R; uncommon: G719X, L861Q, S768I), and would the result open up targeted treatments or trials?
- Has my tumor been tested for ALK fusions (e.g., EML4-ALK), and would the result open up targeted treatments or trials?
- Has my tumor been tested for ROS1 fusions, and would the result open up targeted treatments or trials?
- Of the open trials I found (for example NCT04339218), am I eligible for any — here or at a larger cancer center?
- Do I have a targetable driver (EGFR, ALK, ROS1, RET, METex14, BRAF V600E, NTRK, HER2, KRAS G12C)?
- If no driver, what is my PD-L1 and best IO±chemo plan?
- Is surgery or SBRT an option for my stage? Could oligomet sites be consolidated after response?
- What is our plan if first-line therapy stops working—when and how will we test for resistance?
- Do my co-mutations (STK11/KEAP1/TP53) affect treatment choice?
- How will we monitor and manage IO irAEs and TKI toxicities?
- Would I benefit from pulmonary rehab, nutrition support, or prehab before treatment?
- Am I eligible for clinical trials now or at progression?
- What is the plan for brain surveillance and treatment if needed?
- How will we coordinate supplements/OTC meds to avoid interactions?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?